Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Forte BiosciencesFRA:37T -0.76%33 EV-to-EBIT is -16.05 as of Aug. 17, 2026. GuruFocus rates FRA:37T with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 370 Biotechnology companies, Forte Biosciences ranks worse than 270270% on this metric.
Forte Biosciences (FRA:37T) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Forte Biosciences's Enterprise Value for the quarter that ended in Jun. 2026 was €206.65 Mil.
Forte Biosciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-77.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Forte Biosciences EV-to-EBIT Related Terms
Forte Biosciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Forte Biosciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Forte Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Forte Biosciences EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Forte Biosciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Forte Biosciences's EV-to-EBIT falls into.
Forte Biosciences's current Enterprise Value is €1,242.07 Mil.
Forte Biosciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-77.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Forte Biosciences (FRA:37T) has a EV-to-EBIT of -16.05 as of Aug. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Forte Biosciences and its competitors. According to the industry distribution chart, Forte Biosciences ranks #999999 out of 370 companies in the Biotechnology industry.
Is Forte Biosciences' EV-to-EBIT too high?
Forte Biosciences' current EV-to-EBIT is -16.05. Based on the distribution chart, Forte Biosciences ranks #999999 out of 370 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Forte Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Forte Biosciences' EV-to-EBIT compare to WVE and SVRA?
According to the Biotechnology industry distribution chart, Forte Biosciences ranks #999999 out of 370 companies for EV-to-EBIT. This places Forte Biosciences in the lower half of its industry. The industry median EV-to-EBIT is 16.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.28, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Forte Biosciences and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Forte Biosciences's current EV-to-EBIT is -16.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Forte Biosciences stock overvalued right now?
Forte Biosciences (FRA:37T) has a current EV-to-EBIT of -16.05. The current EV-to-EBIT is -16.05. Forte Biosciences' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Forte Biosciences (FRA:37T), the current EV-to-EBIT is -16.05 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
33GF Score
Get the complete analysis for FRA:37T
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:37T has been successfully added to your 
